Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
25 November 2019 |
Main ID: |
EUCTR2006-005689-38-GB |
Date of registration:
|
19/10/2011 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.
|
Scientific title:
|
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY. |
Date of first enrolment:
|
29/12/2006 |
Target sample size:
|
240 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005689-38 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: double-dummy If controlled, specify comparator, Other Medicinial Product: yes Placebo: yes Other:
|
Phase:
|
Human pharmacology (Phase I):
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III):
Therapeutic use (Phase IV):
|
|
Countries of recruitment
|
Bulgaria
|
Hungary
|
United Kingdom
| | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Patients will be enrolled at Visit 1 into the run-in period if they meet all the following criteria: Written informed consent obtained; Male or female patients aged 15 years and over; Moderate or severe persistent asthma according to the GINA 2005 “Classification of Asthma Severity by Daily Medication Regimen and Response to Treatment”; Patients free of long-acting ß2 agonists treatment (LABAs) at least for 4 weeks before the screening visit and already treated for at least 1 month with inhaled corticosteroids at a stable dose corresponding to mild-medium asthma severity (GINA 2005) (up to 1000 µg BDP CFC or equivalent); Level of asthma control on existing therapy, defined as presence of day-time asthma symptoms > once a week and nocturnal asthma symptoms > twice a month. These findings are to be based on recent medical history and are to be confirmed at the end of the run-in period; Forced expiratory volume in the first second (FEV1) less or equal to 90% of predicted for the patient normal value and not less than 0.9 L in absolute value; Positive response to the reversibility test in the screening visit, defined as an increase of at least 12% and at least 250 mL from pre-dosing value in the measurement of FEV1 30 minutes following 2 puffs (2 x 100 µg) of inhaled salbutamol pMDI; Non-smokers or ex-smokers < 5 pack-year [e.g. less than 1 pack cigarettes (i.e. 20 cigarettes) per day for 5 years or 2 packs cigarettes per day for 2.5 years] and having stopped smoking > 1 year; A co-operative attitude and ability to be trained to correctly use the pMDI and the Aerolizer® inhaler; At the end of the run-in period, the presence of day-time asthma symptoms > once a week (but not every day) and nocturnal asthma symptoms > twice a month is to be confirmed by means of patient interview by the investigator. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: Patients will not be enrolled at Visit 1 into the run-in period if they meet any of the following criteria: Inability to carry out pulmonary function testing; Diagnosis of COPD as defined by the current GOLD guidelines; Current smoker or ex-smoker with total cumulative exposure equal or more than 5 pack-years and/or having stopped smoking one year or less prior to study start; History of near fatal asthma or of a past hospitalisation for asthma in an intensive care unit; History of significant seasonal variation of asthma; Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 4 weeks (e.g. oral corticosteroids intake); Hospitalisation due to asthma during the previous 8 weeks; Patients treated with oral or intravenous corticosteroids in the past 4 weeks or depot injectable corticosteroids in the past 8 weeks; Patients treated with short-acting ß2-agonists in the past 8 hours, short-acting anticholinergics in the past 12 hours, long-acting anticholinergics (i.e. tiotropium bromide) in the past 48 hours, leukotriene modifiers in the past 2 weeks; Patients treated with oral or nebulized bronchodilators in the 4 weeks prior to study start; Patients treated with nebulized corticosteroids in the 4 weeks prior to study start; Patients who have changed their dose or formulation of inhaled or nasal corticosteroids during the previous 4 weeks; Patients treated with fixed combination of inhaled corticosteroids and ß2-agonists (e.g. Seretide®, Symbicort®) during the previous 4 weeks prior to study start; Patients undergoing immunotherapy; Patients treated with a xanthine derivative (e.g. theophylline) any formulation in the 4 weeks prior to study start; Patients treated with sodium cromoglycate or nedocromil sodium in the 4 weeks prior to study start; History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe uncontrolled hypertension, cardiac arrhythmias or any other significant cardiac disease; Patients with a QTc interval (Bazett’s formula) in the ECG test > 450 msec in males or > 470 msec in females; Serum potassium < 3.5 mmol/L or > 6.0mmol/L; Clinically significant or unstable concurrent disease, e.g. uncontrolled diabetes mellitus; uncontrolled hyperthyroidism, significant hepatic impairment, significant pulmonary disease other than asthma (e.g. tuberculosis, lung cancer), gastrointestinal disease (e.g. active peptic ulcer), neurological or haematological autoimmune disorders; Cancer or any other chronic disease with poor prognosis and/or affecting patient status; Pregnant or lactating females or females at risk of pregnancy, i.e. those not making use of an effective contraceptive method (oral contraception, IUD, tubal ligature, double barrier method). A pregnancy test will be performed at screening in women of childbearing potential; History of alcohol or drug abuse; Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers; Allergy, sensitivity or intolerance to beta2-adrenergic agonists and/or study drug formulation ingredients; Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study; Patients who received any investigational new drug within the last 8 weeks.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Persistent asthma
MedDRA version: 14.0
Level: PT
Classification code 10003553
Term: Asthma
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
|
Intervention(s)
|
Product Name: CHF 4226 1 µg - pMDI Product Code: CHF 4226 HFA Pharmaceutical Form: Pressurised inhalation, solution INN or Proposed INN: Carmoterol Hydrochloride CAS Number: 137888-11-0 Current Sponsor code: CHF 4226 Other descriptive name: TA-2005 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Pressurised inhalation, solution Route of administration of the placebo: Inhalation use
Trade Name: FORADIL Product Name: Foradil Pharmaceutical Form: Inhalation powder, hard capsule INN or Proposed INN: Formoterol Fumarate CAS Number: 43229-80-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 12- Pharmaceutical form of the placebo: Inhalation powder, hard capsule Route of administration of the placebo: Inhalation use
|
Primary Outcome(s)
|
Primary end point(s): Trough FEV1 (L) (mean of 23 and 24 hours) at Day 28 (Visit 6) after 4 weeks of dosing.
|
Secondary Objective: - to compare the mean trough 23-24h FEV1 observed with CHF 4226 2 mcg q.d. with the one observed with formoterol 12 mcg bid after 4 weeks of dosing; - to compare the average (AUC standardised for time) FEV1, FVC, FEF25-75 0-3h post evening dose administration and the peak FEV1, FVC, FEF25-75 observed with CHF 4226 with the one observed with placebo and formoterol after the first dose, 1 day, 7 days, 14 days and 4 weeks of dosing; - to compare the mean trough FEV1, FVC, FEF25-75 observed with CHF 4226 with the one observed with placebo and formoterol after 1 day, 7 days, 14 days and 4 weeks of dosing; - to compare the average FEV1, FVC, FEF25-75 12-24h observed with CHF 4226 with the one observed with placebo and formoterol following the last dosing of test treatments on the evening of day 28; - to characterise FEV1, FVC, FEF25-75 following the last dose at 1, 2, 3 hrs and at 12, 13, 15, 15, 16, 18, 20, 22, 23, 24 time points; - to monitor for safety and tolerability.
|
Main Objective: To characterise the mean trough 23-24 hrs FEV1 following 4 weeks of treatment (Visit 6/Day 28) of CHF 4226 2µg given q.d. in the evening and to compare it with placebo.
|
Secondary ID(s)
|
2006-005689-38-HU
|
CCD-0604-PR-0018
|
Source(s) of Monetary Support
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
|